Pulmonary sarcoidosis during interferon therapy: A rare or underestimated event?

Annali Italiani di Medicina Interna

Volumn 19, Issue 1, 2004, Pages 58-62

  Salvio, Antonio ^a   Mormile, Mauro ^b   Giannattasio, Francesco ^a   Varriale, Maria ^a   D'Errico, Tito ^a   Balzano, Brigida ^b   Carratù, Pierluigi ^b   Tufano, Giovanni ^b   Visconti, Mario ^a  

^a Osp S Maria Popolo Incurabili   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chronic hepatitis; Interferon; Sarcoidosis

Indexed keywords

ALPHA2B INTERFERON; DIAGNOSTIC AGENT; GALLIUM; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; COUGHING; DRUG COMBINATION; DYSPNEA; HEPATITIS C; HUMAN; MACROPHAGE ACTIVATION; MALE; SARCOIDOSIS; VIREMIA;

ADULT; COUGH; DRUG THERAPY, COMBINATION; DYSPNEA; GALLIUM RADIOISOTOPES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; MACROPHAGE ACTIVATION; MALE; PREDNISONE; RADIOPHARMACEUTICALS; RIBAVIRIN; RNA, VIRAL; SARCOIDOSIS, PULMONARY; VIREMIA;

EID: 3042528743     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999. Consensus statement. European association for the Study of the Liver. J Hepatol 1999; 30: 956-61.
2. Pietropaoli A, Modrak J, Utell M. Interferon-α therapy associated with the development of sarcoidosis. Chest 1999; 116: 569-72.
3. Bobbio-Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12: 140-2.
4. Fiorani C, Sacchi S, Bonacorsi G, Cosenza M. Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia. Haematologica 2000; 85: 1006-7.
5. Frankova H, Gaja A, Hejlova N. Pulmonary sarcoidosis in a patient with essential thrombocythemia treated with interferon alpha: a short case report. Med Sci Monit 2000; 6: 380-2.
6. Dorr RT. Interferon-α in malignant and viral diseases. Drugs 1993; 45: 177-211.
7. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987; 59: 896-900.
8. Hardman JG, Limbird LE. Goodman & Gilman's the pharmacological basis of therapeutics. New York, NY: McGraw-Hill, 2001: 1337.
9. Hoffmann RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998; 28: 1058-63.
10. Teragawa H, Hondo T, Takahashi K, et al. Sarcoidosis after interferon therapy for chronic active hepatitis C. Intern Med 1996; 35: 19-23.
11. Ravenel JG, McAdams HP, Plankeel JF, Butnor KJ, Sporn TA. Sarcoidosis induced by interferon therapy. AJR Am J Roentgenol 2001; 177: 199-201.
12. Miwa H, Furuya T, Tanaka S, Mizuno Y. Neurosarcoidosis associated with interferon therapy. Eur Neurol 2001; 45: 288-9.
13. Pohl J, Stremmel W, Kallinowski B. Pulmonal sarcoidosis. A rare side effect of interferon-alpha treatment for chronic hepatitis C infection. Z Gastroenterol 2000; 38: 951-5.
14. Vallina E, Garcia Diez A, Gallego M, Villaverde P, Rippe ML, Arribas JM. A case of pulmonary sarcoidosis induced by interferon alfa treatment in a female patient with hepatitis C. An Med Interna 2000; 17: 538-9.
15. Savoye G, Goria O, Herve S, et al. Probable cutaneous sarcoidosis associated with combined ribavirin and interferonalpha therapy for chronic hepatitis C. Gastroenterol Clin Biol 2000; 24: 679.
16. Cacoub P, Sbai A, Frances C, Genesti C, Hausfater P, Piette JC. Systemic sarcoidosis during interferon-alpha therapy for chronic hepatitis C virus infection. Gastroenterol Clin Biol 2000; 24: 364-6.
17. Vander Els NJ, Gerdes H. Sarcoidosis and IFN-alpha treatment. Chest 2000; 117: 294.
18. Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998; 39: 1024-8.
19. Luers C, Sudhop T, Spengler U, Berthold HK. Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection. J Hepatol 1999; 30: 347.
20. Hunninghake G, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
21. Moller DR. Etiology of sarcoidosis. Clin Chest Med 1997; 18: 695-706.
22. Pinkston P, Bitterman PB, Crystal RG. Spontaneous release of interleukin-2 by lung T-lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793-800.
23. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T-lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-95.
24. Brinkmann V, Geiger T, Alkan S, et al. Interferon alpha increases the frequency of interferon gamma-producing human CD4/T cells. J Exp Med 1993; 178: 1655-63.
25. Agostini C, Semenzato G. Common variable immunodeficiency and sarcoidosis: what is the link? Ann Ital Med Int 2002; 17: 77-80.
26. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-91.
27. Sen GC. The interferons. In: Remick DG, Friedland JS, eds. Cytokines in health and disease. New York, NY: Marcel Dekker, 1997: 199-208.
28. Nugent K, Monick M, Hunninghake GW. Pulmonary macrophages from patients with active sarcoidosis spontaneously release immune interferon [abstract]. Clin Res 1984; 32 (Suppl): 434A.
29. Matucci A, Rossi O, Cecchi L, et al. Malattia granulomatosa "sarcoidosi-simile" in pazienti con ipogammaglobulinemia comune variabile. Ann Ital Med Int 2002; 17: 108-16.
30. Hunninghake GW. Role of alveolar macrophage and lung T cell-derived mediators in pulmonary sarcoidosis. Ann NY Acad Sci 1986; 445: 82-90.
31. Walker C, Bauer W, Braun K, et al. Activated T-cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994; 150: 1038-48.
32. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-60.
33. Conlon KC, Urba WJ, Smith JW 2nd, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65: 2237-42.
34. Fels AO, Nathan DF, Cohn ZA. Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta and gamma and 1,25-dihydroxyvitamin D3. J Clin Invest 1987; 80: 381-6.
35. Nakajima H, Nakao A, Watanabe Y, Yoshida S, Iwamoto I. IFN-alpha inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue. J Immunol 1994; 153: 1264-70.
36. Parronchi P, Mohapatra S, Sampognaro S, et al. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996; 26: 697-703.
37. Ezernieks J, Schnarr B, Metz K, Duschl A. The human IgE germline promoter is regulated by interleukin-4, interleukin-13, interferon-alpha and interferon-gamma via an interferon-gamma-activated site and its flanking regions. Eur J Biochem 1996; 240: 667-73.
38. Finkelman FD, Svetic A, Gresser I, et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991; 174: 1179-88.
39. Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996; 97: 309-15.